Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.30
+0.71000.49%
Post-market: 146.300.00000.00%19:53 EDT
Volume:4.54M
Turnover:660.59M
Market Cap:181.51B
PE:-55.95
High:146.35
Open:144.00
Low:142.94
Close:145.59
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.88
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.34
PE(LYR):21.58

Loading ...

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

Reuters
·
Aug 28

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS
·
Aug 28

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Dow Jones
·
Aug 28

Moderna Inc. Stock Falls 5.8%, Underperforms Peers

Dow Jones
·
Aug 27

Gilead Sciences Updates Financial Calendar with Investor Conference Presentations

Reuters
·
Aug 27

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 26

Moderna Inc. Stock Rallies 14.4%, Outperforms Peers

Dow Jones
·
Aug 26

Moderna Inc. Stock Slides 4.3%, Underperforms Peers

Dow Jones
·
Aug 25

Lakefront Biotherapeutics Wins FDA Orphan Drug Status for Gamgertamig in Pemphigus

Reuters
·
Aug 25

EU Commission Approves Gilead Trodelvy-Keytruda Combo for First-Line PD-L1+ Metastatic TNBC

Reuters
·
Aug 24

Gilead - EU Grants Marketing Authorization for Trodelvy with Keytruda in First-Line Pd-L1-Positive Metastatic Tnbc

THOMSON REUTERS
·
Aug 24

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across Pd-L1 Status

THOMSON REUTERS
·
Aug 24

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Gilead Director Jeffrey Bluestone Disposes of 5,000 Common Shares Worth $727,333.60

Reuters
·
Aug 22

Moderna Inc. Stock Advances 8.9%, Outperforms Peers

Dow Jones
·
Aug 22

Gilead Declares Q3 2026 Dividend of R$ 0.24 Per Unit

Reuters
·
Aug 22

Movement Alert|Gilead Sciences Rises 3.07% in Regular Trading, $7.8 Billion Arcellx Acquisition Combined with Q2 Beat Continues to Lift Shares

Market Focus
·
Aug 21

Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block

Simply Wall St.
·
Aug 21

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Aug 21

Moderna Inc. Stock Slips 23.5%, Underperforms Peers

Dow Jones
·
Aug 21